Stammdaten
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Unternehmen & Branche
| Name | RenovoRx, Inc. |
|---|---|
| Ticker | RNXT |
| CIK | 0001574094 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 29,7 Mio. USD |
| Beta | 1,22 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,123,000 | -11,168,000 | -0.32 | 8,095,000 | 5,422,000 |
| 2025-09-30 | 10-Q | 266,000 | -2,912,000 | -0.08 | 11,206,000 | 8,078,000 |
| 2025-06-30 | 10-Q | 422,000 | -2,895,000 | -0.08 | 13,643,000 | 10,641,000 |
| 2025-03-31 | 10-Q | 197,000 | -2,420,000 | -0.08 | 16,014,000 | 13,157,000 |
| 2024-12-31 | 10-K | 43,000 | -8,814,000 | -0.40 | 8,118,000 | 4,478,000 |
| 2024-09-30 | 10-Q | -2,471,000 | -0.10 | 10,031,000 | 7,071,000 | |
| 2024-06-30 | 10-Q | -2,389,000 | -0.10 | 12,004,000 | 9,272,000 | |
| 2024-03-31 | 10-Q | -1,076,000 | -0.07 | 4,788,000 | 1,767,000 | |
| 2023-12-31 | 10-K | -10,232,000 | -0.99 | 1,466,000 | 3,000,000 | |
| 2023-09-30 | 10-Q | -1,421,000 | -0.13 | 3,519,000 | 6,000 | |
| 2023-06-30 | 10-Q | -2,327,000 | -0.22 | 6,314,000 | 1,188,000 | |
| 2023-03-31 | 10-Q | -3,257,000 | -0.36 | 4,561,000 | 3,256,000 | |
| 2022-12-31 | 10-K | -9,889,000 | -1.09 | 7,265,000 | 6,163,000 | |
| 2022-09-30 | 10-Q | -2,136,000 | -0.24 | 9,250,000 | 8,148,000 | |
| 2022-06-30 | 10-Q | -2,594,000 | -0.29 | 11,243,000 | 10,120,000 | |
| 2022-03-31 | 10-Q | -3,003,000 | 13,946,000 | 12,540,000 | ||
| 2021-12-31 | 10-K | -6,324,000 | 16,287,000 | 15,349,000 | ||
| 2021-09-30 | 10-Q | -1,511,000 | 18,178,000 | 17,553,000 | ||
| 2021-06-30 | 10-Q | -1,310,000 | -17,060,000 | |||
| 2021-03-31 | 10-Q | -1,148,000 | -15,762,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Bagai Shaun | Director, Officer, Chief Executive Officer | Open Market Purchase | 24,300 | 0.00 | 0.00 | 0,0% | |
| 2026-03-20 | VOLL MARK | Officer, Chief Financial Officer | Open Market Purchase | 97,200 | 0.00 | 0.00 | 0,0% | |
| 2026-01-21 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 10,000 | 1.00 | 9,975.00 | +135,0% | |
| 2025-12-31 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 9,795 | 0.86 | 8,423.70 | +114,0% | |
| 2025-12-30 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 205 | 0.83 | 169.33 | +2,3% | |
| 2025-12-18 | Bagai Shaun | Director, Officer, Chief Executive Officer | Open Market Purchase | 5,000 | 0.90 | 4,506.50 | +61,0% | |
| 2025-12-17 | Bagai Shaun | Director, Officer, Chief Executive Officer | Open Market Purchase | 5,000 | 0.85 | 4,262.00 | +57,7% | |
| 2025-12-16 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 12,000 | 0.85 | 10,200.00 | +138,1% | |
| 2025-12-05 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 10,000 | 0.96 | 9,600.00 | +129,9% | |
| 2025-11-24 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 12,000 | 0.80 | 9,600.00 | +129,9% | |
| 2025-11-21 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 10,000 | 0.80 | 8,000.00 | +108,3% | |
| 2025-08-25 | Bagai Shaun | Director, Officer, Chief Executive Officer | Open Market Purchase | 5,000 | 0.91 | 4,549.00 | +61,6% | |
| 2025-08-22 | Bagai Shaun | Director, Officer, Chief Executive Officer | Open Market Purchase | 5,000 | 0.95 | 4,747.50 | +64,3% | |
| 2025-06-05 | Agah Ramtin | Director, Officer, Chief Medical Officer | Open Market Purchase | 21,000 | 1.40 | 29,400.00 | +397,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.